SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is a trending topic following reports of scrapped data center expansion plans with OpenAI and looming layoffs, prompting community debate on whether these signify a crucial cost-cutting measure or deeper strains from its ambitious AI infrastructure build-out, with investors eagerly awaiting clarity from its upcoming earnings.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas is trending amid significant market volatility as it announced new multi-million dollar orders for its Sentrycs counter-drone systems and a large border protection contract. The community is actively discussing perceived price suppression and high short interest, with many looking to upcoming earnings and the ongoing global demand for drone defense technology as potential catalysts.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending after securing $2.15 billion in non-dilutive financing at a significantly lower interest rate, confirming Oracle as a key tenant for its Polaris Forge 2 AI campus. The company further solidified its AI infrastructure strategy by committing to a major 1.2 GW power generation project, fueling strong community confidence and anticipation for imminent hyperscaler lease announcements despite recent market volatility.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing significant volatility and sharp drops, driven by geopolitical tensions impacting energy costs for South Korean memory chipmakers and creating broader sector weakness. However, the community is actively debating if this presents a buying opportunity, pointing to Micron's strong AI-driven memory demand, ongoing supply shortages, and high expectations for its upcoming earnings.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

RCAT is trending amidst strong investor debate following reports its FANG drone did not place in the Gauntlet Phase I competition; while some see this as a setback, many remain bullish, citing the company's broader defense drone capabilities and the sector's long-term growth potential fueled by global demand.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

Heightened geopolitical tensions, particularly surrounding Iran and rising oil prices, are fueling significant market volatility and driving conversation around UVIX as traders seek hedges against potential broader market weakness, despite common awareness of the ETF's decay characteristics.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to renewed optimism surrounding its expanding global government contracts, including recent talks in Japan for national data integration, and bolstered by bullish analyst upgrades. This has fueled a sharp divide in community sentiment, with many anticipating a short squeeze driven by its AI and defense momentum, while others express concerns over valuation and market manipulation.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is seeing heightened volatility driven by escalating geopolitical tensions in the Middle East, which has sent oil prices surging and sparked concerns about the broader market and the AI sector. The community is predominantly bearish, actively discussing fears of a significant correction or "Black Monday" type event, leading many to avoid holding positions into the weekend.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is caught in a tug-of-war, with escalating geopolitical tensions and rising oil prices fueling fears of a broader market downturn, while persistent dip-buying continues to defend key technical levels amid community discussions of potential economic shifts and market manipulation.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending following its strategic acquisition of BrewDog assets, a move sparking debate among investors on its potential to significantly bolster global beverage revenue and expand its international footprint. Concurrently, community discussion remains heavily focused on the long-anticipated federal rescheduling of cannabis to Schedule 3, with ongoing speculation about its timeline and direct financial implications for Tilray versus U.S. Multi-State Operators.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What's Driving the Market Sentiment Around Dogwood Therapeutics Inc?

<ul class="summary-bullets"><li>Dogwood also reported a study dropout rate of 4.4%, which the company said is far below rates typically observed with other FDA approved chronic pain medicines.</li><li>The company expects to have top-line results from the trial available during the third quarter (Q3) of 2026.&nbsp;</li><li>Last month, Dogwood said that it has cash on hand of $10.1 million, providing operational runway only through the first quarter of 2026.</li></ul>Dogwood Therapeutics, Inc. (DWTX) said on Monday that patients with chemotherapy induced neuropathic pain (CINP) treated with its painkiller Halneuron demonstrated separation from placebo treated patients in terms of pain improvement over a four-week study. &nbsp;Shares of the company fell 22% at the time of writing and is now poised to log its worst day in over nine months as the update failed to boost investor sentiment.The separation in pain improvement was identified by an independent statistical review committee who reviewed patient treatment data from a mid-stage trial under which 97 patients have completed treatment so far. The company did not <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/12/22/3209363/0/en/Dogwood-Therapeutics-Announces-Positive-Interim-Phase-2b-Clinical-Trial-Results-in-Chemotherapy-Induced-Neuropathic-Pain.html">detail </a>the scale of pain improvement observed in the analysis.The company expects to have top-line results available during the third quarter (Q3) of 2026.Dogwood also reported a study dropout rate of 4.4%, which the company said is far below rates typically observed with other FDA approved chronic pain medicines.<h2 class="st-heading-2">Company Sounds Optimism</h2>According to Dogwood, current study patient enrollment trends are projected to provide statistical power of approximately 80% to 85% to detect a Halneuron treatment difference.“Extrapolation of the current Phase 2b study trends has the potential to represent the first statistically significant trial involving CINP patients under FDA chronic pain study guidance,” said CEO Greg Duncan.Halneuron is Dogwood’s lead product candidate and has been granted fast track designation from the FDA for the treatment of CINP. Last month, the company confirmed enrollment of 100 patients in the mid-stage study for Halneuron. The company is targeting enrolling 200 patients in the study in total.“We are hopeful that positive outcomes in this ongoing Phase 2b trial will set the stage for a Phase 3 registration program in CINP, providing a needed therapeutic option for this patient population of cancer survivors,” Chief Medical Officer Michael Gendreau said on Monday.<h2 class="st-heading-2">Limited Operational Runway</h2>Last month, Dogwood said that it has cash on hand of $10.1 million, providing operational runway only through the first quarter of 2026, before it can announce the results of the ongoing Halneuron trial. &nbsp;The company reported a third quarter basic and diluted net loss per share of $8.20, compared to an analyst estimate of a loss of $1.58 per share.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around DWTX fell from ‘bullish’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.A Stocktwits user now expects the stock to drop as low as $2.<stembedurl>https://www.stocktwits.com/hammerfall43/message/639878419</stembedurl><a href="https://stocktwits.com/symbol/DWTX">DWTX stock</a> has nearly doubled this year. &nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-hits-record-high-as-elon-musk-hints-at-fsd-launch-in-uae-next-month-amid-2018-pay-package-boost/cLeFNmTREMq">Tesla Stock Hits Record High As Elon Musk Hints At FSD Launch In UAE Next Month Amid 2018 Pay Package Boost</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

DWTX Stock Heads For Worst Day In 9 Months As Chemotherapy Pain Drug Interim Study Data Fails To Boost Investor Confidence

The company said that Halneuron demonstrated separation from placebo treated patients in terms of pain improvement but did not detail the scale of the said improvement. 

Equity

The company said that Halneuron demonstrated separation from placebo treated patients in terms of pain improvement but did not detail the scale of the said improvement. 


Dogwood Therapeutics, Inc. (DWTX) shares surged 50% in the pre-market session on Monday after the company announced that it has secured a license to develop Serpin Pharma’s intravenous formulation of SP16 to manage cancer-related pain (CRP).The royalty-free, global license will enable the company to develop SP16 for a broad range of chemotherapy-induced neuropathy symptoms as well.In return, Sepin Pharma and its designated affiliates will get 7.31% of the company’s common stock, on a fully diluted basis. This includes 382,034 shares of DWTX common stock and 179.1878 shares of a new series of non-voting convertible preferred stock, it said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/DWTX">DWTX stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.Dogwood <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/29/3157595/0/en/Dogwood-Therapeutics-Secures-Exclusive-Worldwide-Royalty-Free-License-to-Develop-and-Commercialize-SP16-as-a-Treatment-for-Cancer-Related-Pain-in-an-All-Stock-Transaction-Underscor.html">said</a> that SP16 has demonstrated both anti-inflammatory and neural repair activity. An early-stage trial of the intravenous formulation of SP16, fully funded by the National Cancer Institute, is slated to start patient enrollment in the first half of 2026.“The National Cancer Institute’s funding of the SP16 IV Phase 1b program obviates the need to use our existing capital in the near-term to advance SP16 into clinical development,” CEO Greg Duncan said.The company also noted that SP16 could complement its lead candidate Halneuron, which has demonstrated statistically significant and clinically meaningful pain reductions in general cancer pain, as well as chemotherapy-induced neuropathic pain, respectively.DWTX stock has more than tripled this year and risen by about 79% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-lobby-announces-new-website-to-connect-patients-with-manufacturer-direct-patient-programs/chDuciYR3JJ">Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Programs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug 

In return for the license, Sepin Pharma and its designated affiliates will get 7.31% of Dogwood’s common stock, on a fully diluted basis.

Shares of Dogwood Therapeutics Inc. rose over 18% in premarket trading Friday, following a jaw-dropping 370% surge in the previous session.&nbsp;Trading volume was over 62 times the daily average, with retail investors on Stocktwits making it the most discussed biotech stock before the bell.While there was no fresh news on Friday, the rally appears to stem from an&nbsp;earlier announcement.&nbsp;Dogwood disclosed on Tuesday that it plans to begin dosing the first patient in its Phase 2b HALT-CINP trial in the first quarter of 2025.&nbsp;The trial evaluates Halneuron, a non-opioid therapy aimed at alleviating neuropathic pain linked to chemotherapy.The company’s focus on pain and fatigue-related disorders has generated excitement, bolstered by its non-opioid analgesic and antiviral platforms.&nbsp;Retail attention on Stocktwits has skyrocketed. The stock saw an 8,500% jump in message volume on Thursday, with&nbsp;its retail&nbsp;following increasing by 18% in a single day.&nbsp;<stembedurl>https://stocktwits.com/OFFC18/message/601301523</stembedurl><stembedurl>https://stocktwits.com/BullsEye2000/message/601306713</stembedurl>Dogwood stock is up over 400% year-to-date and has lost 95% over the past 12 months.&nbsp;The massive surge has reignited attention, although its low liquidity and early-stage pipeline make it a volatile bet.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Dogwood Therapeutics Becomes Most Actively Discussed Biotech Stock Among Retail Traders After Stunning 370% Surge

The company’s focus on pain and fatigue-related disorders has generated excitement, bolstered by its non-opioid analgesic and antiviral platforms.

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

DWTX
Dogwood Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest DWTX News

DWTXDogwood Therapeutics Inc.